Disulfiram
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DISULFIRAM |
|---|---|
| Type | Drug |
| Aliases | AntabuseEsperalДисульфірам |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Aldehyde dehydrogenase (ALDH) inhibitor |
|---|---|
| Mechanism | Irreversibly inhibits hepatic aldehyde dehydrogenase, causing acetaldehyde accumulation when alcohol is ingested. This produces the "disulfiram-alcohol reaction" — flushing, nausea/vomiting, tachycardia, hypotension, dyspnea, headache — intended to deter drinking via aversion. Effective only with motivated, adherent patients in supervised settings. FDA-approved AUD pharmacotherapy (third-line after naltrexone and acamprosate). |
| Typical dosing | PO: 500 mg once daily × 1-2 weeks, then 250 mg once daily for maintenance (range 125-500 mg). Patient must be alcohol-free ≥12 h before initiation (and informed of disulfiram-alcohol reaction). Supervised administration substantially improves outcomes vs. self-administered. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Warnings
- Severe (potentially fatal) disulfiram-alcohol reaction — never administer to a patient in alcohol intoxication or without their full knowledge and consent
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Third-line AUD pharmacotherapy (after naltrexone and acamprosate). Aversive mechanism — works only with motivated patients; supervised administration improves outcomes. CV contraindications limit use. Alcohol cessation is a cancer- prevention intervention (HCC, CRC, esophageal SCC, breast). Source cited is closest in-KB until NIAAA/APA AUD sources land in source-stub workstream.
Used By
No reverse references found in the YAML corpus.